Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 5
1986 1
1987 12
1988 12
1989 19
1990 21
1991 22
1992 24
1993 46
1994 63
1995 68
1996 95
1997 95
1998 111
1999 109
2000 117
2001 130
2002 149
2003 164
2004 220
2005 219
2006 213
2007 295
2008 396
2009 502
2010 605
2011 782
2012 929
2013 1078
2014 1349
2015 1447
2016 1600
2017 1798
2018 2024
2019 2285
2020 2714
2021 3283
2022 3363
2023 3513
2024 3773

Text availability

Article attribute

Article type

Publication date

Search Results

29,751 results

Results by year

Filters applied: . Clear all
Page 1
Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists.
Jensen EL, Israelsen M, Krag A. Jensen EL, et al. Hepatol Commun. 2024 Oct 10;8(11):e0561. doi: 10.1097/HC9.0000000000000561. eCollection 2024 Nov 1. Hepatol Commun. 2024. PMID: 39392766 Review.
In this review, we examine the molecular and clinical effects of glucagon-like peptide 1 receptor agonists, focusing on their direct hepatic steatohepatitis and liver fibrosis but also the indirect influence on cardiometabolic risk factors and e …
In this review, we examine the molecular and clinical effects of glucagon-like peptide 1 receptor agonist …
Efficacy of Chronic Use of Sodium-Glucose Co-transporter 2 Inhibitors on the Prevention of Contrast-Induced Acute Kidney Injury in Patients with Type 2 Diabetes Mellitus Following Coronary Procedures: A Systematic Review and Meta-Analysis.
Dimitriadis K, Vakka A, Pyrpyris N, Apostolos A, Beneki E, Stathopoulou E, Giannou P, Tsioufis P, Iliakis P, Aznaouridis K, Petras D, Tsioufis K. Dimitriadis K, et al. Am J Cardiovasc Drugs. 2024 Oct 11. doi: 10.1007/s40256-024-00684-y. Online ahead of print. Am J Cardiovasc Drugs. 2024. PMID: 39392560
This study aims to evaluate the efficacy of chronic use of sodium-glucose co-transporter 2 (SGLT2) inhibitors on the prevention of CI-AKI in patients with type 2 DM following coronary procedures. ...Subgroup analyses were performed to eva …
This study aims to evaluate the efficacy of chronic use of sodium-glucose co-transporter 2 (SGLT2) inh …
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
Kawaguchi T, Fujishima Y, Wakasugi D, Io F, Sato Y, Uchida S, Kitajima Y. Kawaguchi T, et al. J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158-z. Online ahead of print. J Gastroenterol. 2024. PMID: 39392481
BACKGROUND & AIM: SGLT2 inhibitors (SGLT2i) improve hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) and MASLD. ...
BACKGROUND & AIM: SGLT2 inhibitors (SGLT2i) improve hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) and MASLD. …
Empagliflozin ameliorates olfactory bulbectomy-induced depression by mitigating oxidative stress and possible involvement of brain derived neurotrophic factor in diabetic rats.
Borikar SP, Chitode GV, Tapre DN, Lokwani DK, Jain SP. Borikar SP, et al. Int J Neurosci. 2024 Oct 11:1-18. doi: 10.1080/00207454.2024.2414270. Online ahead of print. Int J Neurosci. 2024. PMID: 39392472
Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has recently reported to prevent the depression as chronic animal model. ...
Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has recently reported to preve …
Cardiac-derived CTRP9 mediates the protection of empagliflozin against diabetes-induced male subfertility in mice.
Mu Y, Luo LB, Huang R, Shen ZY, Huang D, Zhao SH, Yang J, Ma ZG. Mu Y, et al. Clin Sci (Lond). 2024 Oct 11:CS20241477. doi: 10.1042/CS20241477. Online ahead of print. Clin Sci (Lond). 2024. PMID: 39392219
Previous studies have shown beneficial effects of empagliflozin (Empa), a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), on diabetes and cardiovascular outcomes in patients with diabetes. However, whether Empa could ameliorate diabetes mellitus (DM)-ind …
Previous studies have shown beneficial effects of empagliflozin (Empa), a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT …
Obesity Management in Youth with Duchenne Muscular Dystrophy: A Review of Metformin and Alternative Pharmacotherapies.
Goldman V, Ryabets-Lienhard A, Howard L, Kohli R, Sousa E, Patel P, Marpuri I, Vidmar AP. Goldman V, et al. Child Obes. 2024 Oct 11. doi: 10.1089/chi.2024.0297. Online ahead of print. Child Obes. 2024. PMID: 39392010 Review.
Included terms were DMD and topiramate, phentermine, metformin, glucagon-like peptide-1 receptor agonist, semaglutide, and liraglutide. Eligible studies were cataloged to examine obesity pharmacotherapy, side effect profiles, and clinical outcom …
Included terms were DMD and topiramate, phentermine, metformin, glucagon-like peptide-1 receptor agonist, …
Deciphering the role of endothelial granulocyte macrophage-CSF in chronic inflammation associated with HIV.
Panigrahi S, Mayne E, Louw S, Funderburg NT, Chakraborty A, Jacobson JM, Carpenter SM, Lederman MM, Freeman ML, Sieg SF. Panigrahi S, et al. iScience. 2024 Sep 11;27(10):110909. doi: 10.1016/j.isci.2024.110909. eCollection 2024 Oct 18. iScience. 2024. PMID: 39391731 Free PMC article.
Exposure to sodium-glucose cotransporter-2 (SGLT2) inhibitors reduced glucose uptake, GM-CSF release, and ED in LPS-activated endothelial cells ex vivo, and PWH treated with SGLT2 inhibitors for diabetes had significantly lower plasma GM-CSF levels than non-diabetic …
Exposure to sodium-glucose cotransporter-2 (SGLT2) inhibitors reduced glucose uptake, GM-CSF release, and ED in LPS-activated endothe …
29,751 results
You have reached the last available page of results. Please see the User Guide for more information.